このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

第一選択(1L)転移性非扁平上皮非小細胞肺癌(NSCLC)における維持オラパリブまたは維持ペメトレキセドとペムブロリズマブの研究(MK-7339-006、KEYLYNK-006)

2026年9月3日 更新者:Merck Sharp & Dohme LLC

転移性非扁平上皮非小細胞肺癌の参加者の一次治療におけるペメトレキセド/プラチナ(カルボプラチンまたはシスプラチン)と組み合わせたペムブロリズマブとその後のペムブロリズマブおよび維持オラパリブ対維持ペメトレキセドの第3相試験

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).

調査の概要

詳細な説明

This study has 2 phases: an Induction Phase of up to ~4 Cycles (up to ~12 weeks [cycle =3 weeks]) and a Maintenance Phase of up to ~31 cycles of pembrolizumab (cycle = 3 weeks]); total pembrolizumab treatment duration will be up to ~35 cycles (up to ~2 years). In the Induction Phase, participants receive pembrolizumab plus pemetrexed plus platinum (carboplatin or cisplatin, at the investigator's discretion). In the Maintenance Phase, participants with a partial or complete disease response or with stable disease after completing four cycles of induction therapy and who meet eligibility criteria will be randomly assigned to receive pembrolizumab plus maintenance olaparib OR pembrolizumab plus maintenance pemetrexed. In the Maintenance Phase, participants receive pembrolizumab for up to 31 cycles (cycle = 3 weeks) plus maintenance olaparib OR maintenance pemetrexed until progressive disease (PD), intolerable toxicities, or physician decision.

Qualified participants in each study arm of the maintenance phase (Pembrolizumab plus Olaparib and Pembrolizumab plus Pemetrexed) who complete up to ~35 cycles of pembrolizumab (up to ~2 years [cycle =3 weeks]) may be eligible to receive a second course of pembrolizumab for up to ~17 cycles (up to ~1 additional year). Per protocol, response or progression during the second pembrolizumab course will not be counted towards patient reported outcomes (PROs) or efficacy outcome measures and adverse events during the second pembrolizumab course will not be counted towards safety outcome measures.

研究の種類

介入

入学 (実際)

1003

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35205
        • Alabama Oncology Bruno Cancer Center ( Site 0001)
      • Muscle Shoals、Alabama、アメリカ、35661
        • Northwest Alabama Cancer Center, PC ( Site 0002)
    • California
      • Burbank、California、アメリカ、91505
        • Disney Family Cancer Center ( Site 0005)
    • Florida
      • Boca Raton、Florida、アメリカ、33486
        • Boca Raton Regional Hospital ( Site 0018)
      • Orange City、Florida、アメリカ、32763
        • Mid-Florida Cancer Centers ( Site 0022)
      • Tampa、Florida、アメリカ、33612
        • Moffitt Cancer Center ( Site 0024)
    • Georgia
      • Columbus、Georgia、アメリカ、31904
        • Columbus Regional Research Institute ( Site 0098)
    • Illinois
      • Chicago、Illinois、アメリカ、60608
        • Mount Sinai Hospital Medical Center ( Site 0032)
      • Rolling Meadows、Illinois、アメリカ、60008
        • Oncology of Northshore ( Site 0033)
    • Indiana
      • Merrillville、Indiana、アメリカ、46410
        • Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0036)
    • Maryland
      • Baltimore、Maryland、アメリカ、21239
        • Medstar Good Samaritan Hospital ( Site 0040)
    • Michigan
      • Detroit、Michigan、アメリカ、48201
        • Barbara Ann Karmanos Cancer Institute ( Site 0041)
    • Mississippi
      • Hattiesburg、Mississippi、アメリカ、39401
        • Hattiesburg Clinic ( Site 0045)
    • Montana
      • Billings、Montana、アメリカ、59102
        • Frontier Oncology ( Site 0080)
      • Bozeman、Montana、アメリカ、59715
        • Bozeman Health Deaconness Cancer Center ( Site 0046)
    • North Carolina
      • Cary、North Carolina、アメリカ、27518
        • Waverly Hematology Oncology ( Site 0081)
    • Tennessee
      • Knoxville、Tennessee、アメリカ、37920
        • University of Tennessee Medical Center Knoxville ( Site 0060)
      • Knoxville、Tennessee、アメリカ、37916
        • Thompson Cancer Survival Center ( Site 2812)
    • Texas
      • The Woodlands、Texas、アメリカ、77380
        • Renovatio Clinical ( Site 0062)
    • Washington
      • Spokane Valley、Washington、アメリカ、99216
        • Cancer Care Northwest ( Site 0071)
      • Córdoba、アルゼンチン、X5004SHP
        • Clínica Universitaria Reina Fabiola ( Site 0505)
      • Santa Fe、アルゼンチン、S3000AOL
        • Sanatorio Privado San Geronimo S.R.L ( Site 0510)
    • Buenos Aires
      • Bahía Blanca、Buenos Aires、アルゼンチン、B8001HXM
        • Hospital Italiano Regional del Sur ( Site 0509)
      • Ciudad Autonoma de Buenos Aires、Buenos Aires、アルゼンチン、C1199ABB
        • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0511)
      • Ciudad Autónoma de Buenos Aires、Buenos Aires、アルゼンチン、C1280AEB
        • Hospital Britanico de Buenos Aires ( Site 0500)
    • Córdoba Province
      • Río Cuarto、Córdoba Province、アルゼンチン、X5800AEV
        • Instituto Medico Rio Cuarto ( Site 0501)
    • Santa Fe Province
      • Rosario、Santa Fe Province、アルゼンチン、S2000KZE
        • Centro Oncológico de Rosario ( Site 0507)
    • Tucumán Province
      • San Miguel de Tucumán、Tucumán Province、アルゼンチン、T4000IAK
        • Centro Medico San Roque ( Site 0506)
      • Birmingham、イギリス、B9 5SS
        • Birmingham Heartlands Hospital ( Site 1910)
    • London, City of
      • London、London, City of、イギリス、EC1M 6BQ
        • Barts Health NHS Trust - St Bartholomew s Hospital ( Site 1923)
      • London、London, City of、イギリス、SW10 9NH
        • Chelsea and Westminster Hospital ( Site 1901)
    • Suffolk
      • Bury St Edmunds、Suffolk、イギリス、IP33 2QZ
        • West Suffolk Hospitals NHS Trust ( Site 1919)
    • United Kingdom
      • Edinburgh、United Kingdom、イギリス、EH4 2XU
        • Western General Hospital, Edinburgh ( Site 1924)
    • Wales
      • Swansea、Wales、イギリス、SA2 8QA
        • Singleton Hospital ( Site 1909)
    • Worcestershire
      • Colchester、Worcestershire、イギリス、CO4 5JL
        • Colchester General Hospital ( Site 1911)
      • Kyiv、ウクライナ、03115
        • Kyiv City Clinical Oncology Centre ( Site 2210)
    • Cherkasy Oblast
      • Cherkasy、Cherkasy Oblast、ウクライナ、18009
        • Cherkasy Regional Oncology Dispensary ( Site 2211)
    • Dnipropetrovsk Oblast
      • Dnipro、Dnipropetrovsk Oblast、ウクライナ、49102
        • Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 2201)
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk、Ivano-Frankivsk Oblast、ウクライナ、76018
        • MI Precarpathian Clinical Oncology Center ( Site 2204)
    • Kharkiv Oblast
      • Kharkiv、Kharkiv Oblast、ウクライナ、61024
        • Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2212)
      • Kharkiv、Kharkiv Oblast、ウクライナ、61070
        • CNPE "Regional Center of Oncology"-Thoracic organs ( Site 2205)
    • Kirovohrad Oblast
      • Kropyvnitskiy、Kirovohrad Oblast、ウクライナ、25006
        • PP PPC Acinus Medical and Diagnostic Centre ( Site 2209)
    • Kyivska Oblast
      • Khodosovka、Kyivska Oblast、ウクライナ、08173
        • Medical Center Asklepion LLC ( Site 2234)
      • Kyiv、Kyivska Oblast、ウクライナ、03126
        • Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2213)
      • Kyiv、Kyivska Oblast、ウクライナ、03039
        • Medical Center Verum ( Site 2230)
    • Odesa Oblast
      • Odesa、Odesa Oblast、ウクライナ、65055
        • MI Odessa Regional Oncological Centre ( Site 2208)
    • Zakarpattia Oblast
      • Uzhhorod、Zakarpattia Oblast、ウクライナ、88000
        • Central City Clinical Hospital ( Site 2207)
    • New South Wales
      • Liverpool、New South Wales、オーストラリア、2170
        • Liverpool Hospital ( Site 1201)
      • Wollongong、New South Wales、オーストラリア、2500
        • Southern Medical Day Care Centre ( Site 1200)
    • Queensland
      • Townsville、Queensland、オーストラリア、4814
        • Townsville General Hospital ( Site 1202)
    • Victoria
      • Clayton、Victoria、オーストラリア、3168
        • Monash Cancer Centre ( Site 1205)
      • Vienna、オーストリア、1210
        • Krankenhaus Nord - Klinik Floridsdorf ( Site 1300)
    • State of Vienna
      • Vienna、State of Vienna、オーストリア、1145
        • Social Medical Center - Otto Wagner Hospital ( Site 1301)
    • Tyrol
      • Innsbruck、Tyrol、オーストリア、6020
        • Innsbruck LKH ( Site 1302)
    • Upper Austria
      • Linz、Upper Austria、オーストリア、4020
        • Ordensklinikum Linz GmbH Elisabethinen ( Site 1307)
      • Wels、Upper Austria、オーストリア、4600
        • Klinikum Wels-Grieskirchen ( Site 1304)
    • British Columbia
      • North Vancouver、British Columbia、カナダ、V7L 2L7
        • Lions Gate Hospital ( Site 0106)
      • Victoria、British Columbia、カナダ、V8R 6V5
        • BC Cancer - Victoria ( Site 0109)
    • Nova Scotia
      • Halifax、Nova Scotia、カナダ、B3H 2Y9
        • Queen Elizabeth II Health Sciences Centre ( Site 0107)
    • Ontario
      • Greater Sudbury、Ontario、カナダ、P3E 5J1
        • Health Sciences North Research Institute ( Site 0115)
      • Kitchener、Ontario、カナダ、N2G 1G3
        • Waterloo Regional Health Network (WRHN) ( Site 0117)
      • Newmarket、Ontario、カナダ、L3Y 2P9
        • Stronach Regional Cancer Centre ( Site 0101)
    • Quebec
      • Greenfield Park、Quebec、カナダ、J4V 2H1
        • CISSS de la Monteregie-Centre ( Site 0114)
      • Montreal、Quebec、カナダ、H3T 1M5
        • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0110)
      • Montreal、Quebec、カナダ、H2X 3E4
        • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0105)
      • Rimouski、Quebec、カナダ、G5L 5T1
        • Centre de Sante et des Services Sociaux de Rimouski-Neigette ( Site 0104)
      • Sherbrooke、Quebec、カナダ、J1H 5N4
        • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103)
    • Antioquia
      • Medellín、Antioquia、コロンビア、050030
        • Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0604)
    • Atlántico
      • Barranquilla、Atlántico、コロンビア、080020
        • Clinica de la Costa S.A.S. ( Site 0608)
    • Bogota D.C.
      • Bogotá、Bogota D.C.、コロンビア、110221
        • Administradora Country S.A. ( Site 0603)
      • Bogotá、Bogota D.C.、コロンビア、111321
        • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 0601)
      • Barcelona、スペイン、08003
        • Hospital del Mar ( Site 1702)
      • Seville、スペイン、41014
        • Hospital Universitario Nuestra Senora de Valme ( Site 1703)
      • Zaragoza、スペイン、50009
        • Hospital Clinico Lozano Blesa ( Site 1700)
    • Madrid
      • Pozuelo de Alarcón、Madrid、スペイン、28223
        • Hospital Universitario Quiron Madrid ( Site 1701)
    • Valenciana, Comunitat
      • Valencia、Valenciana, Comunitat、スペイン、46010
        • Hospital Clinico Universitario de Valencia ( Site 1706)
      • Adana、トルコ(Türkiye)、01120
        • Baskent Unv. Adana Uyg. ve Arast. Hastanesi ( Site 2101)
      • Ankara、トルコ(Türkiye)、06500
        • Gazi Universitesi Tip Fakultesi ( Site 2104)
      • Ankara、トルコ(Türkiye)、06800
        • Ankara Bilkent Sehir Hastanesi ( Site 2105)
      • Istanbul、トルコ(Türkiye)、34093
        • Bezmialem Vakif Univ. Tıp Fakultesi Hastanesi Tibbi Onkoloji Bolumu ( Site 2107)
      • Istanbul、トルコ(Türkiye)、34722
        • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2103)
      • Izmir、トルコ(Türkiye)、35040
        • Ege Universitesi Tip Fakultesi ( Site 2109)
      • Kayseri、トルコ(Türkiye)、38039
        • Erciyes Universitesi Tip Fakultesi ( Site 2108)
      • Samsun、トルコ(Türkiye)、55139
        • Ondokuz Mayıs Universitesi-Oncology department ( Site 2106)
    • Tekirdas
      • Tekirdağ、Tekirdas、トルコ(Türkiye)、59100
        • Namik Kemal Universitesi Tip Fakultesi ( Site 2100)
      • Hamburg、ドイツ、22087
        • Katholisches Marienkrankenhaus gGmbH ( Site 1522)
    • Bavaria
      • Aschaffenburg、Bavaria、ドイツ、63739
        • Studienzentrum Aschaffenburg ( Site 1525)
      • Munich、Bavaria、ドイツ、80336
        • Klinikum der LMU ( Site 1500)
      • Munich、Bavaria、ドイツ、81925
        • Klinikum Bogenhausen Staedt. Klinikum Muenchen GmbH ( Site 1523)
      • Regensburg、Bavaria、ドイツ、93053
        • Universitaetsklinikum Regensburg ( Site 1512)
      • Würzburg、Bavaria、ドイツ、97074
        • Klinikum Wuerzburg Mitte gGmbH ( Site 1509)
    • Hesse
      • Frankfurt am Main、Hesse、ドイツ、60590
        • Universitaetsklinikum Frankfurt ( Site 1513)
      • Immenhausen、Hesse、ドイツ、34376
        • Pneumologische Lehrklinik Universitaet Goettingen ( Site 1501)
    • Lower Saxony
      • Göttingen、Lower Saxony、ドイツ、37075
        • Universitaetsmedizin Goettingen ( Site 1507)
    • North Rhine-Westphalia
      • Bonn、North Rhine-Westphalia、ドイツ、53127
        • Universitaetsklinikum Bonn ( Site 1524)
      • Essen、North Rhine-Westphalia、ドイツ、45136
        • Kliniken Essen Mitte ( Site 1517)
    • Rhineland-Palatinate
      • Koblenz、Rhineland-Palatinate、ドイツ、56068
        • InVo-Institut fuer Versorgungsforschung in der Onkologie ( Site 1514)
    • Thuringia
      • Erfurt、Thuringia、ドイツ、99089
        • Helios Klinikum Erfurt GmbH ( Site 1502)
      • Wellington、ニュージーランド、6021
        • Capital & Coast District Health Board - Wellington Hospital ( Site 1101)
    • Manawatu-Wanganui
      • Palmerston North、Manawatu-Wanganui、ニュージーランド、4414
        • MidCentral DHB Palmerston North Hospital ( Site 1102)
    • Ain
      • Vandœuvre-lès-Nancy、Ain、フランス、54519
        • Institut De Cancerologie De Lorraine ( Site 1409)
    • Aisne
      • Chauny、Aisne、フランス、02300
        • Centre Hospitalier De Chauny ( Site 1411)
    • Calvados
      • Caen、Calvados、フランス、14033
        • CHU Caen ( Site 1406)
    • Maine-et-Loire
      • Angers、Maine-et-Loire、フランス、49100
        • CHU Angers ( Site 1405)
    • Moselle
      • Vantoux、Moselle、フランス、57070
        • Hopital Robert Schuman ( Site 1402)
    • Puy-de-Dome
      • Clermont-Ferrand、Puy-de-Dome、フランス、63011
        • Centre Jean Perrin ( Site 1407)
    • Pyrenees-Atlantiques
      • Pau、Pyrenees-Atlantiques、フランス、64000
        • Centre Hospitalier de Pau ( Site 1412)
    • Seine-Maritime
      • Rouen、Seine-Maritime、フランス、76000
        • CHU de Rouen ( Site 1403)
    • Val-de-Marne
      • Saint-Mandé、Val-de-Marne、フランス、94163
        • Hopital d'Instruction des Armees Begin ( Site 1413)
      • Rio de Janeiro、ブラジル、20231-050
        • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0203)
      • São Paulo、ブラジル、01246-000
        • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0200)
      • São Paulo、ブラジル、01321-001
        • BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0214)
      • São Paulo、ブラジル、01321-001
        • Hospital Paulistano - Amil Clinical Research ( Site 0207)
    • Ceará
      • Fortaleza、Ceará、ブラジル、60351-030
        • Instituto do Cancer do Ceara ( Site 0201)
    • Estado de Bahia
      • Salvador、Estado de Bahia、ブラジル、41253-190
        • Hospital Sao Rafael ( Site 0212)
    • Pará
      • Belém、Pará、ブラジル、66053-000
        • Oncologica do Brasil ( Site 0210)
    • Rio Grande do Sul
      • Bento Gonçalves、Rio Grande do Sul、ブラジル、95700-000
        • Hospital Tacchini ( Site 0208)
      • Porto Alegre、Rio Grande do Sul、ブラジル、90050-170
        • Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0209)
      • Santa Cruz do Sul、Rio Grande do Sul、ブラジル、96810-110
        • Saint Gallen Instituto de Oncologia ( Site 0206)
    • Santa Catarina
      • Florianópolis、Santa Catarina、ブラジル、88020-210
        • YNOVA Pesquisa Clinica ( Site 0215)
      • Itajaí、Santa Catarina、ブラジル、88301-220
        • Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0202)
      • Joinville、Santa Catarina、ブラジル、89201-260
        • Centro de Hematologia e Oncologia ( Site 0205)
    • São Paulo
      • Sao Jose Rio Preto、São Paulo、ブラジル、15080-000
        • Hospital de Base de Sao Jose de Rio Preto ( Site 0204)
    • Greater Poland Voivodeship
      • Konin、Greater Poland Voivodeship、ポーランド、62-500
        • Przychodnia Lekarska Komed ( Site 2416)
      • Poznan、Greater Poland Voivodeship、ポーランド、61-693
        • MED-POLONIA Sp. z o.o. ( Site 2419)
    • Lesser Poland Voivodeship
      • Krakow、Lesser Poland Voivodeship、ポーランド、31-202
        • Krakowski Szpital Specjalistyczny im Jana Pawla II ( Site 2420)
    • Lower Silesian Voivodeship
      • Zgorzelec、Lower Silesian Voivodeship、ポーランド、59-900
        • Wielospecjalistyczny Szpital SPZOZ w Zgorzelcu ( Site 2404)
    • Masovian Voivodeship
      • Warsaw、Masovian Voivodeship、ポーランド、02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2418)
    • Silesian Voivodeship
      • Racibórz、Silesian Voivodeship、ポーランド、47-400
        • Szpital Rejonowy im. dr Jozefa Rostka ( Site 2402)
    • Warmian-Masurian Voivodeship
      • Olsztyn、Warmian-Masurian Voivodeship、ポーランド、10-357
        • Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie ( Site 2417)
      • Brasov、ルーマニア、500152
        • Spitalul PDR Medlife ( Site 2509)
    • Bucharest
      • Bucharest、Bucharest、ルーマニア、013823
        • MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 2502)
    • Cluj
      • Cluj-Napoca、Cluj、ルーマニア、407280
        • S.C. Radiotherapy Center Cluj S.R.L ( Site 2507)
      • Cluj-Napoca、Cluj、ルーマニア、400015
        • Cardiomed SRL Cluj-Napoca ( Site 2504)
    • Constanța County
      • Ovidiu、Constanța County、ルーマニア、905900
        • Ovidius Clinical Hospital OCH ( Site 2501)
    • Dolj
      • Craiova、Dolj、ルーマニア、200542
        • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2508)
    • Timiș County
      • Timișoara、Timiș County、ルーマニア、300239
        • Policlinica Oncomed SRL ( Site 2505)
    • Moscow
      • Moscow、Moscow、ロシア、115478
        • Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 2000)
      • Moscow、Moscow、ロシア、119991
        • First Moscow State Medical University n.a. I.M.Sechenov ( Site 2024)
      • Moscow、Moscow、ロシア、125284
        • Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2009)
      • Moscow、Moscow、ロシア、125367
        • FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 2006)
    • Moscow Oblast
      • Balashikha、Moscow Oblast、ロシア、143900
        • Moscow Regional Oncological Dispensary ( Site 2028)
    • Nizhny Novgorod Oblast
      • Nizhny Novgorod、Nizhny Novgorod Oblast、ロシア、603081
        • Nizhniy Novgorod Region Oncology Dispensary ( Site 2026)
    • Omsk Oblast
      • Omsk、Omsk Oblast、ロシア、644013
        • Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site 2010)
    • Samara Oblast
      • Samara、Samara Oblast、ロシア、443031
        • SBHI Samara Regional Clinical Oncology Dispensary ( Site 2016)
    • Sankt-Peterburg
      • Saint Petersburg、Sankt-Peterburg、ロシア、194291
        • SBHI Leningrad Regional Clinical Hospital ( Site 2002)
      • Saint Petersburg、Sankt-Peterburg、ロシア、195271
        • SPb Central Clinical Railway Hospital ( Site 2003)
      • Saint Petersburg、Sankt-Peterburg、ロシア、197758
        • National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 2004)
      • Saint Petersburg、Sankt-Peterburg、ロシア、198255
        • SPb SBHI City Clinical Oncological Dispensary ( Site 2001)
    • Tatarstan, Respublika
      • Kazan'、Tatarstan, Respublika、ロシア、420029
        • Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2021)
      • Kaohsiung City、台湾、833
        • Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0907)
      • Taichung、台湾、40447
        • China Medical University Hospital ( Site 0904)
      • Tainan、台湾、70457
        • National Cheng Kung University Hospital ( Site 0905)
      • Taipei、台湾、104
        • Mackay Memorial Hospital ( Site 0902)
      • Taipei、台湾、100
        • National Taiwan University Hospital ( Site 0900)
      • Taoyuan、台湾、333
        • Chang Gung Medical Foundation.Linkou Branch ( Site 0903)
      • Fukuoka、日本、8108563
        • National Hospital Organization Kyushu Medical Center ( Site 0805)
      • Niigata、日本、951-8566
        • Niigata Cancer Center Hospital ( Site 0808)
      • Okayama、日本、700-8558
        • Okayama University Hospital ( Site 0810)
      • Osaka、日本、541-8567
        • Osaka International Cancer Institute ( Site 0809)
      • Tokyo、日本、135-8550
        • Cancer Institute Hospital of JFCR ( Site 0800)
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、460-0001
        • National Hospital Organization Nagoya Medical Center ( Site 0806)
      • Nagoya、Aichi-ken、日本、464-8681
        • Aichi Cancer Center ( Site 0803)
    • Chiba
      • Kashiwa、Chiba、日本、2778577
        • National Cancer Center Hospital East ( Site 0801)
    • Ishikawa-ken
      • Kanazawa、Ishikawa-ken、日本、920-8641
        • Kanazawa University Hospital ( Site 0811)
    • Kanagawa
      • Yokohama、Kanagawa、日本、241-8515
        • Kanagawa Cancer Center ( Site 0807)
    • Miyagi
      • Sendai、Miyagi、日本、981-0914
        • Sendai Kousei Hospital ( Site 0812)
    • Osaka
      • Hirakata、Osaka、日本、573-1191
        • Kansai Medical University Hospital ( Site 0804)
      • Sakai、Osaka、日本、591-8555
        • National Hospital Organization Kinki-chuo Chest Medical Center ( Site 0813)
    • Shizuoka
      • Suntogun、Shizuoka、日本、411-8777
        • Shizuoka Cancer Center ( Site 0802)
      • Seoul、韓国、03080
        • Seoul National University Hospital ( Site 1000)
      • Seoul、韓国、08308
        • Korea University Guro Hospital ( Site 1008)
    • Kyonggi-do
      • Goyang-si、Kyonggi-do、韓国、10408
        • National Cancer Center ( Site 1006)
      • Suwon、Kyonggi-do、韓国、16247
        • The Catholic University of Korea St. Vincent s Hospital ( Site 1003)
      • Suwon、Kyonggi-do、韓国、16499
        • Ajou University Hospital ( Site 1004)
    • Kyongsangnam-do
      • Jinju、Kyongsangnam-do、韓国、52727
        • Gyeongsang National University Hospital ( Site 1005)
    • North Chungcheong
      • Cheongju-si、North Chungcheong、韓国、28644
        • Chungbuk National University Hospital ( Site 1002)
    • Seoul
      • Songpa-gu、Seoul、韓国、05505
        • Asan Medical Center ( Site 1007)

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Have a histologically or cytologically confirmed diagnosis nonsquamous NSCLC.

  2. Have stage IV nonsquamous NSCLC.

  3. Have confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated.

  4. Have measurable disease based on RECIST 1.1.

  5. Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.

    Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.

  6. Have a life expectancy of at least 3 months.

  7. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status assessed within 7 days prior to the administration of study intervention.

  8. Have not received prior systemic treatment for their advanced/metastatic NSCLC.

  9. Have adequate organ function.

  10. Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for 180 days afterwards.

  11. Male participants must refrain from donating sperm, and female participants must refrain from donating eggs to others or freeze/store for her own use during the treatment period and for 180 days afterwards.

Exclusion Criteria:

  1. Has predominantly squamous cell histology NSCLC.
  2. Has a known additional malignancy that is progressing or has progressed within the past 3 years requiring active treatment.
  3. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  4. Has a severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
  5. Has a known hypersensitivity to any components or excipients of cisplatin, carboplatin, pemetrexed, or olaparib.
  6. Has an active autoimmune disease that has required systemic treatment in past 2 years.
  7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
  8. Has a known history of human immunodeficiency virus (HIV) infection, a known history of hepatitis B infection, or known active hepatitis C virus infection.
  9. Has interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment.
  10. Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor.
  11. Has received prior therapy with an agent directed to programmed cell death ligand 1 (PD-L1), anti PD-L2, or directed to a stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
  12. Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
  13. Has completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib

For the Induction Phase, participants receive 4 cycles (up to ~12 weeks [cycle = 3 weeks]): pembrolizumab 200 mg intravenous (IV) on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of each cycle (Cycles 1 through 4).

If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. The participant can continue to receive maintenance olaparib until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to ~35 cycles (up to ~2 years [cycle = 3 weeks]).

IV infusion

他の名前:
  • MK-3475
  • キイトルーダ®

Oral Tablet

他の名前:
  • リムパーザ®

IV infusion

他の名前:
  • プラチノール®
  • プラチノール®-AQ

IV infusion

他の名前:
  • パラプラチン®

IV infusion

他の名前:
  • アリムタ®
アクティブコンパレータ:Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed

For the Induction Phase, participants receive 4 cycles (up to ~12 weeks [cycle = 3 weeks]): pembrolizumab 200 mg IV on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin AUC 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of each cycle (Cycles 1 through 4).

If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance pemetrexed 500 mg/m^2 IV on Day 1 of each 3-week cycle. The participant can continue to receive maintenance pemetrexed until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to ~35 cycles (up to ~2 years [cycle = 3 weeks]).

IV infusion

他の名前:
  • MK-3475
  • キイトルーダ®

IV infusion

他の名前:
  • プラチノール®
  • プラチノール®-AQ

IV infusion

他の名前:
  • パラプラチン®

IV infusion

他の名前:
  • アリムタ®

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Progression-free Survival (PFS)
時間枠:Up to ~31 months

PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was analyzed by the non-parametric Kaplan-Meier (K-M) method. The protocol specified final analysis of PFS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~31 months
Overall Survival (OS)
時間枠:Up to ~51 months

OS was defined as the time from randomization to death due to any cause. OS was analyzed by the non-parametric K-M method. Participants without documented death at the time of analyses were censored at the date of last known to be alive. The protocol specified final analysis of OS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~51 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants Who Experience One or More Adverse Events (AEs)
時間枠:Up to ~5 years

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

Up to ~5 years
Number of Participants Who Discontinue Study Treatment Due to an AE
時間枠:Up to ~5 years

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

Up to ~5 years
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score
時間枠:Baseline and Week 24

EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score
時間枠:Up to ~24 months

EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome was not done in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score
時間枠:Baseline and Week 24

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 cough (Item 1) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-LC13 Cough (Item 1) Scale Score
時間枠:Up to ~24 months

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 1). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
時間枠:Baseline and Week 24

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 chest pain (Item 10) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
時間枠:Up to ~24 months

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in chest pain (Item 10). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
時間枠:Baseline and Week 24

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
時間枠:Up to ~24 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
時間枠:Baseline and Week 24

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
時間枠:Up to ~24 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Medical Director、Merck Sharp & Dohme LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年6月28日

一次修了 (実際)

2024年2月7日

研究の完了 (実際)

2026年1月30日

試験登録日

最初に提出

2019年6月3日

QC基準を満たした最初の提出物

2019年6月3日

最初の投稿 (実際)

2019年6月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月28日

QC基準を満たした最後の更新が送信されました

2026年9月3日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する